Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 247,759,536
  • Shares Outstanding, K 5,606,688
  • Annual Sales, $ 41,908 M
  • Annual Income, $ 9,616 M
  • 60-Month Beta 0.74
  • Price/Sales 5.88
  • Price/Cash Flow 15.06
  • Price/Book 3.73
Trade PFE with:

Options Overview Details

View History
  • Implied Volatility 21.92%
  • Historical Volatility 14.21%
  • IV Percentile 36%
  • IV Rank 11.97%
  • IV High 60.64% on 12/09/20
  • IV Low 16.65% on 06/11/21
  • Put/Call Vol Ratio 0.27
  • Today's Volume 121,342
  • Volume Avg (30-Day) 162,372
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 2,160,089
  • Open Int (30-Day) 2,564,933

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.07
  • Number of Estimates 5
  • High Estimate 1.22
  • Low Estimate 0.96
  • Prior Year 0.72
  • Growth Rate Est. (year over year) +48.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.31 +1.45%
on 09/17/21
48.28 -8.99%
on 08/25/21
-4.44 (-9.18%)
since 08/24/21
3-Month
38.82 +13.19%
on 06/30/21
51.86 -15.27%
on 08/18/21
+4.75 (+12.12%)
since 06/24/21
52-Week
33.36 +31.71%
on 02/26/21
51.86 -15.27%
on 08/18/21
+8.18 (+22.87%)
since 09/24/20

Most Recent Stories

More News
The Latest: Washington state to give Pfizer boosters to some

OLYMPIA, Wash. -- The Washington state Department of Health says it will immediately start offering booster doses of the Pfizer-BioNTech COVID-19 vaccine to certain people after recommendations from the...

JNJ : 164.36 (-0.30%)
PFE : 43.94 (-0.57%)
US booster shots start, even as millions remain unprotected

The U.S. launched a campaign to offer boosters of Pfizer's COVID-19 vaccine to millions of Americans on Friday even as federal health officials stressed the real problem remains getting first shots to...

PFE : 43.94 (-0.57%)
JNJ : 164.36 (-0.30%)
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for...

PFE : 43.94 (-0.57%)
OPK : 3.75 (-3.35%)
Top Research Reports for Home Depot, salesforce & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE).

CRM : 285.63 (+2.80%)
IBM : 137.49 (+0.56%)
PFE : 43.94 (-0.57%)
HD : 337.49 (+0.47%)
ZTS : 204.73 (+0.01%)
SONY : 117.61 (+1.83%)
AstraZeneca (AZN) Inks Deal to Enter Novel RNA Therapeutic Space

AstraZeneca (AZN) inks a deal to gain the rights to the self-amplifying RNA platform developed by the Imperial College London.

AZN : 60.35 (+1.46%)
PFE : 43.94 (-0.57%)
MRNA : 430.14 (-5.38%)
BNTX : 333.48 (-5.53%)
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility

AZN : 60.35 (+1.46%)
PFE : 43.94 (-0.57%)
MRNA : 430.14 (-5.38%)
NVAX : 248.16 (-3.55%)
Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only

The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.

JNJ : 164.36 (-0.30%)
PFE : 43.94 (-0.57%)
MRNA : 430.14 (-5.38%)
BNTX : 333.48 (-5.53%)
Growth Hormone Deficiency Market: Industry Insights By Growth, Emerging Trends And Forecast By 2028

Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution...

TEVA : 8.95 (-1.10%)
NOVN : 8.14 (-3.78%)
PFE : 43.94 (-0.57%)
LLY : 231.68 (-0.22%)
MRK : 73.61 (+0.77%)
7 Best ETFs of the First Nine Months of 2021

We highlight seven ETFs from different segments that have outperformed and gained more than 40% in the first nine months of 2021.

PFE : 43.94 (-0.57%)
XRT : 94.96 (-0.36%)
FCG : 15.88 (+0.70%)
PXE : 17.98 (+0.50%)
REMX : 109.84 (-1.95%)
XSVM : 50.36 (+0.08%)
URNM : 75.65 (-7.02%)
GERM : 43.34 (-2.32%)
CDC leader adds people with risky jobs to COVID booster list

The Centers for Disease Control and Prevention on Thursday endorsed booster shots for millions of older or otherwise vulnerable Americans, opening a major new phase in the U.S vaccination drive against...

JNJ : 164.36 (-0.30%)
PFE : 43.94 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

3rd Resistance Point 44.90
2nd Resistance Point 44.65
1st Resistance Point 44.30
Last Price 43.94
1st Support Level 43.70
2nd Support Level 43.45
3rd Support Level 43.10

See More

52-Week High 51.86
Fibonacci 61.8% 44.79
Last Price 43.94
Fibonacci 50% 42.61
Fibonacci 38.2% 40.43
52-Week Low 33.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar